The United Nations Office at Geneva
Multimedia Newsroom
STORYLINE
Injectable HIV medicines deal to provide access to generic lifesaver in developing nations
A landmark agreement has been reached allowing for the production of low-cost, injectable HIV medicines in some 90 developing countries where more the majority of infections occur, UNITAID said on Friday.
Selected manufacturers will be able to develop, manufacture and supply lower-cost generic versions of long-acting Cabotegravir (CAB-LA), in line with a deal reached with pharmaceutical firm ViiV Healthcare (ViiV).
“The Medicines Patent Pool, a structure created and largely funded by UNITAID, has reached a voluntary licensing agreement for patents relating to Cabotegravir long-acting, an injectable form of HIV prevention, or PrEP, to generic formulations of the product in least-developed, low-income, lower-middle income and sub-Saharan African countries,” said UNITAID spokesperson Hervé Verhoosel.
The deal is significant because Cabotegravir injections are only needed once every few months. Increasing its supply at a cost that is affordable to low-income countries could help to overcome the stigma that’s associated with taking daily HIV pills - and the burden of having to remember to take them.
“In the 90 countries that we are talking about, 80 countries are royalty-free, meaning that ViiV won’t ask for any royalty on the product and for 10 of those countries, ViiV is asking for a smaller-than-usual royalty,” Mr. Verhoosel explained.
The agreement comes after UNITAID-led discussions began in May this year with ViiV, a subsidiary of pharma giant GlaxoSmithkline. It is only seven months since Cabotegravir LA received regulatory approval.
But the process of selecting the companies that will develop, manufacture and supply generic versions of Cabotegravir will take much longer.
“This product will not be there for everybody, that’s first for people who are there the most at risk,” said Mr. Verhoosel, who noted that the cost of the medicine in the US when it comes onstream there “really soon”, was likely to be around $20,000. “That’s a lot of money; that’s why that product cannot be used in low and middle-income countries.”
According to UNITAID, the deal offers the possibility of making the injectable prophylactic medicine available in 90 countries where more than 70 per cent of all new HIV infections occurred in 2020.
Up to three drug manufacturers will be licensed to develop the product on a generic basis to avoid supply and distribution issues. “That’s done in a way that we’re sure (that) one, it’s easy for logistics, two…availability, and three, of course, that it will help to bring the cost of the generic version down”, said Mr. Verhoosel.
ends
STORY: Injectable HIV Prevention Medicines Deal - UNITAID
TRT: 02’05”
SOURCE: UNTV CH
RESTRICTIONS: NONE
LANGUAGE: ENGLISH/NATS
ASPECT RATIO: 16:9
DATELINE: Friday 29 July 2022, GENEVA, SWITZERLAND
SHOTLIST
- Medium shot, UN Geneva flag alley.
- Wide shot, press room with panel of speakers, journalists, TV camera on tripod.
- SOUNDBITE (ENGLISH) Hervé Verhoosel, UNITAID: “The Medicines Patent Pool, a structure created and largely funded by UNITAID, has reached a voluntary licensing agreement for patents relating to cabotegravir long-acting, an injectable form of HIV prevention, or PrEP, to generic formulations of the product in least-developed, low-income, lower-middle income and sub-Saharan African countries.”
- Medium shot, lateral, podium speakers.
- SOUNDBITE (ENGLISH) Hervé Verhoosel, UNITAID: “In the 90 countries that we are talking about, 80 countries are royalty-free, meaning that ViiV (ViiV Healthcare) don’t ask any royalty on the product and for 10 of those countries ViiV is asking for a smaller-than-usual royalty.”
- Wide shot, journalists, TV camera, light panel.
- SOUNDBITE (ENGLISH) Hervé Verhoosel, UNITAID: “This product will not be there for everybody, that’s first for people who are there the most at risk. That’s a product that’s available in the US, and the price of that product for one year in the US for example is approximately 20,000 US dollars, and that’s a lot of money; that’s why that product cannot be used in low and middle-income countries.”
- Medium shot, journalists seated at tables, TV camera.
- SOUNDBITE (ENGLISH) Hervé Verhoosel, UNITAID: “This licence will actually give the option to three different generic manufacturers to develop the product on a generic base. That means that the price that those companies will have we don’t know yet, but that will not only be one company, that will be three different companies and that’s done in a way that we’re sure one, that it’s easy for logistics, two, that ensuring availability, and three, of course, that it will help to bring the cost of the generic version down.”
- Medium shot, journalists.
- Wide shot, journalists, TV camera and light panel.
- Medium shot, journalist.
- Medium shot, journalists, side shot.
Similar Stories
1
48
1
1
Edited News | UNOG
A ceremony marking the completion of the construction of the Portail des Nations, a soon-to-open visitors centre for the UN in Geneva, was held today for diplomats from around the world who have gathered in the Swiss city for the opening session of the Human Rights Council.
1
1
1
Edited News | OHCHR , UNOG
UN Human Rights Chief Volker Türk on Monday delivered his opening remarks to the 61str session of the Human Rights Council in Geneva.
1
10
1
1
Edited News | HRC , SG
In Geneva, delegates from more than 120 countries gathered on Monday to mark 20 years of the UN Human Rights Council and a shared commitment to international law, amid runaway global instability and conflict, amid runaway global instability and conflict.
1
1
1
Edited News | OHCHR , UNOG
The UN Human Rights Office has published a report on the grave human rights abuses suffered by the hundreds of thousands of people trafficked into scam operations mostly in southeast Asia.
1
1
1
Edited News | OHCHR , UNOG
UN Human Rights Spokesperson Marta Hurtado briefed journalists on a UN report detailing child trafficking by gangs and how it is putting Haiti’s future at risk.
1
1
1
Edited News | WHO , IFRC , UN WOMEN
Ukraine’s women at breaking point after four years of war as attacks on energy, healthcare continue – UN humanitarians
Four years into Russia’s full-scale invasion, millions in Ukraine struggle to keep the lights on and heat their homes, with the crisis taking a particular toll on women, humanitarians warned on Friday.
1
1
1
Edited News | OHCHR , UNOG
“Migrants, refugees and asylum-seekers in Libya are subjected to ruthless and systematic human rights violations and abuses, which include killings, torture, sexual violence and trafficking,” the UN Human Rights Spokesperson Thameen Al-Kheetan told the bi-weekly press conference in Geneva today.
1
1
1
Edited News | UNICEF , IOM
Four years of war in Ukraine: Childhood has ‘moved underground’, displacement continues – UN humanitarians
Civilian suffering shows no sign of letting up in Ukraine as the four-year-mark of Russia’s full-scale invasion nears amid attacks on energy infrastructure, blackouts and freezing temperatures, UN humanitarians warned on Tuesday.
1
1
1
Edited News | OHCHR , UNOG
The UN Human Rights Office on Friday voiced concerns about the severe impacts on human rights of the socio-economic crisis in Cuba.
1
1
1
Edited News | WFP
Madagascar: ‘Overwhelming’ destruction, surging needs after back-to-back cyclones – WFP
Some 10 days after tropical cyclone Fytia brought heavy rains and flooding to Madagascar, cyclone Gezani has left the island’s main port in ruins, the UN World Food Programme (WFP) said on Friday.
1
1
1
Edited News | OHCHR
UN rights chief urges de-escalation in Tigray amid rising tensions and violence.
1
1
1
Edited News | UNICEF , WHO , OHCHR
In Sudan, sick and starving children ‘wasting away’ – UN humanitarians
Relentless violence, famine and disease are picking off Sudan’s children while attacks on healthcare and a lack of aid access hamper efforts to help them, UN humanitarian agencies warned on Tuesday.